* Minerva Neurosciences Inc NERV.OQ NERV.O is expected
to show
no change in quarterly revenue when it reports results on May 2
(estimated).
*
* Refinitiv's mean analyst estimate for Minerva
Neurosciences Inc
is for a loss of $1.29 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Minerva
Neurosciences Inc is $7.5, above its last closing price
of $2.70.
This summary was machine generated April 28 at 17:38 GMT. All
figures in US dollars unless otherwise stated